COSCIENS Biopharma Acquires Nualtis for $15.0 Million
COSCIENS acquired Nualtis for a $15.0 million base price, including $9.0 million in cash and $6.0 million deferred, plus an EBITDA-based earn-out. It also reported a $2.0 million non-cash PGX equipment impairment and approximately $14.3 million of convertible debentures issued to date.
COSCIENS acquired Nualtis for a $15.0M base price, including $9.0M cash and $6.0M deferred, plus an EBITDA-based earn-out. It reported a $2.0M non-cash PGX equipment impairment and approximately $14.3M of convertible debentures issued to date.Material DetailsContext by AI AnalystThis is an early-st…